Liquid Biopsies Become More Common for Gastric and GI Cancers
Joseph Kim, MD, discusses the utility of liquid biopsies in patients with gastric or gastrointestinal cancer at the 2020 GI Cancers Symposium held by the American Society of Clinical Oncology.
Joseph Kim, MD, chief of the Division of Surgical Oncology at the University of Kentucky, discusses the utility of liquid biopsies in patients with gastric or gastrointestinal (GI) cancer at the 2020 GI Cancers Symposium held by the American Society of Clinical Oncology.
Kim says that liquid biopsies are currently in their infancy for diagnostics in the GI setting, and this is also the case for patients with gastric cancer. Although liquid biopsies are being tested in a number of cancers, it is particularly important for patients with gastric cancer because it can be difficult to get enough tissue from the tumor to get all the genetic testing physicians need for these patients with a tissue biopsy.
When using liquid biopsies, physicians will be provided with an avenue to get that data they may have otherwise not been able to obtain with a tissue biopsy. As liquid biopsies become more widely used, there is the potential to change the kinds of treatments that physicians can offer patients in this setting.
<< View more from the 2020 Gastrointestinal Cancers Symposium
The Impact of the Gut Microbiome in Young Patients With Colorectal Cancer
February 15th 2021In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.
Listen
Durvalumab Plus Chemo Continues to Improve Survival in Biliary Tract Cancer
April 16th 2024Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced biliary tract cancer continued to improve overall survival vs chemotherapy alone.
Read More
